Inventor · disambiguated record
Scott Koenig
Also filed as: KOENIG SCOTT · KOENIG SCOTT R
57 granted patents·31 pending applications·1,818 citations·filing 1994–2025
99Inventor score
Files withMACROGENICS INC43MEDIMMUNE INC14KOENIG SCOTT13MEDIMMUNE LLC4ST JUDE CHILDRENS RES HOSPITAL2
Top patents by PatentIndex Score
88 records- 0198US8946387B2FcγRIIB specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2008·Granted Feb 3, 2015·82 cites·25 claims
- 0298US8193318B2FcγRIIB specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2008·Granted Jun 5, 2012·77 cites·6 claims
- 0398US7553489B2Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatmentMEDIMMUNE LLC·Filed 2006·Granted Jun 30, 2009·44 cites·18 claims
- 0498US6818216B2Anti-RSV antibodiesMEDIMMUNE INC·Filed 2001·Granted Nov 16, 2004·165 cites·80 claims
- 0597US8800907B2Mobile device case with retractor reel assembly for user-provided headphonesKOENIG SCOTT·Filed 2011·Granted Aug 12, 2014·22 cites·15 claims
- 0697US8652466B2Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibitingSTAVENHAGEN JEFFREY B·Filed 2007·Granted Feb 18, 2014·50 cites·40 claims
- 0797US8216574B2Engineering Fc antibody regions to confer effector functionSTAVENHAGEN JEFFREY·Filed 2009·Granted Jul 10, 2012·65 cites·25 claims
- 0897US8044180B2FcγRIIB specific antibodies and methods of use thereofMACROGENICS INC·Filed 2008·Granted Oct 25, 2011·52 cites·40 claims
- 0997US7425619B2FcγRIIB specific antibodies and methods of use thereofMACROGENICS INC·Filed 2003·Granted Sep 16, 2008·156 cites·40 claims
- 1097US7229619B1Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatmentMEDIMMUNE INC·Filed 2000·Granted Jun 12, 2007·114 cites·80 claims
- 1196US8187593B2FcγRIIB specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2008·Granted May 29, 2012·63 cites·15 claims
- 1296US7847082B2Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatmentMEDIMMUNE LLC·Filed 2009·Granted Dec 7, 2010·26 cites·33 claims
- 1396US7179900B2Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatmentMEDIMMUNE INC·Filed 2003·Granted Feb 20, 2007·45 cites·80 claims
- 1496US6855493B2Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatmentMEDIMMUNE INC·Filed 2001·Granted Feb 15, 2005·72 cites·73 claims
- 1596US6689369B2Immunogenic pneumococcal protein and vaccine compositions thereofMEDIMMUNE INC·Filed 2001·Granted Feb 10, 2004·71 cites·19 claims
- 1696US6280667B1Process for making thermoplastic-biofiber composite materials and articles including a poly(vinylchloride) componentANDERSEN CORP·Filed 1999·Granted Aug 28, 2001·180 cites·58 claims
- 1795US11623959B2PD-1-binding molecules and methods of use thereofMACROGENICS INC·Filed 2020·Granted Apr 11, 2023·6 cites·23 claims
- 1895US10711069B2Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibitingMACROGENICS INC·Filed 2017·Granted Jul 14, 2020·7 cites·16 claims
- 1995US10577422B2PD-1-binding molecules and methods of use thereofMACROGENICS INC·Filed 2016·Granted Mar 3, 2020·19 cites·10 claims
- 2095US10160806B2Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereofMACROGENICS INC·Filed 2015·Granted Dec 25, 2018·18 cites·34 claims
- 2195US7425620B2FcγRIIB-specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2003·Granted Sep 16, 2008·91 cites·15 claims
- 2295US7323172B2Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatmentMEDIMMUNE INC·Filed 2004·Granted Jan 29, 2008·48 cites·12 claims
- 2394US9708408B2Methods for the treatment of disease using immunoglobulins having Fc Regions with altered affinities for FcγRactivating and FcγRinhibitingMACROGENICS INC·Filed 2014·Granted Jul 18, 2017·9 cites·10 claims
- 2494US7635568B2Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatmentMEDIMMUNE LLC·Filed 2004·Granted Dec 22, 2009·39 cites·95 claims
- 2593US11858991B2LAG-3-binding molecules and methods of use thereofMACROGENICS INC·Filed 2021·Granted Jan 2, 2024·2 cites·18 claims
- 2693US6833356B1Pneumococcal protein homologs and fragments for vaccinesMEDIMMUNE INC·Filed 2000·Granted Dec 21, 2004·42 cites·8 claims
- 2793US6565849B2Methods of enhancing activity of vaccines and vaccine compositionsMEDIMMUNE INC·Filed 2001·Granted May 20, 2003·45 cites·19 claims
- 2892US8530627B2FcγRIIB specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2008·Granted Sep 10, 2013·18 cites·29 claims
- 2991US11421031B2Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereofMACROGENICS INC·Filed 2020·Granted Aug 23, 2022·2 cites·22 claims
- 3091US9487587B2Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereofMACROGENICS INC·Filed 2014·Granted Nov 8, 2016·9 cites·14 claims
- 3191US8968730B2FcγRIIB specific antibodies and methods of use thereofKOENIG SCOTT·Filed 2008·Granted Mar 3, 2015·15 cites·16 claims
- 3291US8663634B2Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicityKOENIG SCOTT·Filed 2006·Granted Mar 4, 2014·25 cites·12 claims
- 3388US11072653B2LAG-3-binding molecules and methods of use thereofMACROGENICS INC·Filed 2016·Granted Jul 27, 2021·4 cites·17 claims
- 3488US10954301B2Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereofMACROGENICS INC·Filed 2016·Granted Mar 23, 2021·3 cites·8 claims
- 3588US9056906B2Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicityKOENIG SCOTT·Filed 2007·Granted Jun 16, 2015·12 cites·8 claims
- 3686US11098119B2Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereofMACROGENICS INC·Filed 2018·Granted Aug 24, 2021·2 cites·14 claims
- 3786US11078279B2Combination therapy for the treatment of cancerMACROGENICS INC·Filed 2016·Granted Aug 3, 2021·5 cites·20 claims
- 3886US10633443B2Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereofMACROGENICS INC·Filed 2015·Granted Apr 28, 2020·3 cites·9 claims
- 3986US2024018261A1METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS ALTERED AFFINITIES FOR FcyRActivating and FcyRInhibitingMACROGENICS INC·Filed 2023·Application pending·0 cites
- 4085US7435421B2Derivatives of choline binding proteins for vaccinesMEDIMMUNE INC·Filed 2005·Granted Oct 14, 2008·6 cites·6 claims
- 4184US11639386B2Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereofMACROGENICS INC·Filed 2020·Granted May 2, 2023·1 cites·10 claims
- 4284US9908938B2Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereofMACROGENICS INC·Filed 2014·Granted Mar 6, 2018·6 cites·27 claims
- 4384US2025304685A1Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereofMACROGENICS INC·Filed 2025·Application pending·0 cites
- 4484US2025313628A1Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereofMACROGENICS INC·Filed 2025·Application pending·0 cites
- 4583US10717778B2Bispecific molecules comprising an HIV-1 envelope targeting armUNIV DUKE·Filed 2015·Granted Jul 21, 2020·3 cites·20 claims
- 4683US6368599B1Caulobacter LPS immunoadjuvantsUNIV BRITISH COLUMBIA·Filed 2000·Granted Apr 9, 2002·17 cites·7 claims
- 4782US12173051B2Bispecific molecules comprising an HIV-1 envelope targeting armUNIV DUKE·Filed 2020·Granted Dec 24, 2024·1 cites·16 claims
- 4882US6962701B2Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune responseMEDIMMUNE INC·Filed 2003·Granted Nov 8, 2005·8 cites·13 claims
- 4981US2023399399A1Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses ThereofMACROGENICS INC·Filed 2023·Application pending·0 cites
- 5080US6863893B2Derivatives of choline binding proteins for vaccinesMEDIMMUNE INC·Filed 2002·Granted Mar 8, 2005·10 cites·14 claims
Showing the top 50 of 88 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Scott Koenig files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →